Dosing schedule for erbb2 anticancer agents

Details Dosing schedule for erbb2 anticancer agents Dosing schedule for erbb2 anticancer agents

A - Human Necessities

61

K

A61K 31/517 (2006.01) A61K 31/506 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2536140

The invention is directed to methods for the a method for treating overexpression of the erbB2 in a mammal in need of treatment by administering to the mammal a therapeutically effective amount of a first inhibitor of an erbB2 receptor and then, after an interval of less than 24 hours, administering to the mammal from one to six therapeutically effective amounts of the same or different inhibitor of the erbB2 receptor. The invention is also directed to a slow daily infusion of the erbB2 inhibitor. The overexpression of the erbB2 receptor can result in abnormal cell growth and lead to cancer. By the methods of the invention, the efficacy and safety of the inhibitors is increased. The invention is also directed to kits for facilitating the dose administration method of the invention.

L'invention se rapporte à des méthodes de traitement de la surexpression d'erbB2 chez un mammifère nécessitant un traitement, consistant à administrer audit mammifère une quantité thérapeutique efficace d'un premier inhibiteur d'un récepteur d'erbB2, et à administrer ensuite au mammifère, après un intervalle inférieur à 24 heures, une à six doses thérapeutiques efficaces du même inhibiteur ou d'un inhibiteur différent du récepteur d'erbB2. L'invention se rapporte également à une perfusion quotidienne lente de l'inhibiteur d'erbB2. La surexpression du récepteur d'erbB2 peut aboutir à une croissance cellulaire anormale et provoquer un cancer. Grâce aux méthodes selon l'invention, l'efficacité et l'innocuité des inhibiteurs sont accrues. L'invention concerne également des trousses permettant de faciliter la mise en oeuvre du procédé d'administration posologique selon l'invention.

Affiliated with

Also associated with

Rating

Dosing schedule for erbb2 anticancer agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dosing schedule for erbb2 anticancer agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dosing schedule for erbb2 anticancer agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1630208